Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Description

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

Conditions

Alcohol Use Disorder (AUD)

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Condition
Alcohol Use Disorder (AUD)
Intervention / Treatment

-

Contacts and Locations

Providence

Brown University, Providence, Rhode Island, United States, 20923

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female, 18 years of age
  • * Meet the DSM-5 criteria for AUD
  • * Desire to reduce or quit alcohol drinking
  • * Breath alcohol (BrAC) = 0.00 at each visit
  • * In good health as confirmed by medical history, physical examination and lab tests
  • * Willing to adhere to the study procedures
  • * Understand informed consent and questionnaires in English at an 8th grade level
  • * Women who are breastfeeding or /positive urine test for pregnancy
  • * CrCl\<60mL/min
  • * Suicide attempt in the last three months
  • * Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline
  • * Current use of medication that may interact with doxazosin and/or yohimbine
  • * History of allergy to any alpha receptor blockers
  • * Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8
  • * Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening
  • * Treatment with any alpha-blocker
  • * Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG.
  • * Baseline hypotension defined as BP reading lower than 90/60 mmHg
  • * Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brown University,

Carolina L Haass-Koffler, PHARMD, PHD, PRINCIPAL_INVESTIGATOR, Brown University

Study Record Dates

2025-12-20